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Abstract
Introduction: Despite the efficacy and tolerability of modern antiretroviral therapy (ART), many patients with advanced AIDS
prescribed these regimens do not achieve viral suppression or immune reconstitution as a result of poor adherence, drug
resistance, or both. The clinical outcomes of continued ART prescription for such patients have not been well characterized.
Methods: We examined the causes and predictors of all-cause mortality, AIDS-defining conditions, and serious non-AIDS-
defining events among a cohort of participants in a clinical trial of pre-emptive therapy for CMV disease. We focused on
participants who, despite ART had failed to achieve virologic suppression and substantive immune reconstitution.
Results: 233 ART-receiving participants entered with a median baseline CD4+ T cell count of 30/mm3 and plasma HIV RNA
of 5 log10 copies/mL. During a median 96 weeks of follow-up, 24.0% died (a mortality rate of 10.7/100 patient-years); 27.5%
reported a new AIDS-defining condition, and 22.3% a new serious non-AIDS event. Of the deaths, 42.8% were due to an
AIDS-defining condition, 44.6% were due to a non-AIDS-defining condition, and 12.5% were of unknown etiology.
Decreased risk of mortality was associated with baseline CD4+ T cell count $25/mm3 and lower baseline HIV RNA.
Conclusions: Among patients with advanced AIDS prescribed modern ART who achieve neither virologic suppression nor
immune reconstitution, crude mortality percentages appear to be lower than reported in cohorts of patients studied a decade
earlier. Also, in contrast to the era before modern ART became available, nearly half of the deaths in our modern-era study
were caused by serious non-AIDS-defining events. Even among the most advanced AIDS patients who were not obtaining
apparent immunologic and virologic benefit from ART, continued prescription of these medications appears to alter the
natural history of AIDS—improving survival and shifting the causes of death from AIDS- to non-AIDS-defining conditions.
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Introduction
Potent antiretroviral therapies have drastically improved the
disease-free survival of HIV-infected patients and have provided
millions of years of additional life to those receiving these drugs
[1,2]. However, the benefits of such therapies have not been
universal and HIV-infected individuals in resource-rich regions
continue to die prematurely [3,4], particularly those who fail to
achieve immune reconstitution from antiretroviral therapy [5].
Nevertheless, even among patients with advanced AIDS (i.e.,
absolute CD4+ T cell count ,50/mm3) who fail to achieve any
substantive immune reconstitution, suppression of HIV replication
with ART results in survival rates that far exceed the optimal rates
reported before the modern ART era. For example, in the
COHERE study of 75,336 HIV+ patients observed between 1997
and 2010, the mortality rate among patients with a most recent
absolute CD4+ T cell count ,50/mm3 was only 6.5% per year of
suppressed viral load [6]. In contrast, in a number of randomized
trials conducted in the early 1990s that were designed to test
combination nucleoside reverse transcriptase inhibitor (NRTI)
drug combinations or prophylaxis to prevent M. avium complex
infection, crude mortality percentages of 32%–40% over one to
two years of follow-up were reported [7–9].
However, it is not clear what clinical impact continuing to
prescribe ART for late-stage AIDS patients who demonstrate
neither suppression of HIV replication nor substantive improvement
in absolute CD4+T cell count has in the modern ART era. Results
of a pivotal, randomized, strategic treatment interruption study
conducted in the modern ART era suggested that continuing ART
in AIDS patients with multi-drug-resistant HIV and unsuppressed
viremia has clinical efficacy compared to temporarily stopping
treatment, although not with respect to survival [10]. However,
the degree of medication adherence in this trial was very high, and
patients randomized to continue failing ART had some degree of
immune reconstitution during follow-up (an average increase in
the median absolute CD4+ T cell count by approximately 50
cells/mm3). There are also little data regarding the cause of death
in patients with advanced AIDS who fail to achieve either virologic
suppression or substantive immune reconstitution with continued
ART. Whether the causes of death among these individuals mirror
those of the pre-modern ART era or are influenced by receipt of
ART is not clear.
To address these questions, we examined mortality and its
causes among a cohort of participants in a trial of pre-emptive
therapy for cytomegalovirus viremia. The cohort consisted of
patients who were receiving a combination of at least three
antiretroviral agents for at least three months, had failed to
suppress HIV replication (plasma HIV RNA level greater than
1,000 copies/mL), and had not achieved an absolute CD4+ T cell
count above 100 cells/mm3 prior to enrollment.
Methods
Participants
The Biomedical Institutional Review Board at the University of
North Carolina and the institutional review boards at each
participating AIDS Clinical Trials Group study sites approved the
protocol and all participants provided verbal and written informed
consent. AIDS Clinical Trials Group (ACTG) study A5030 was a
prospective, double-blind, placebo-controlled, multi-centered,
randomized trial conducted at academic centers across the US
between 2000 and 2005. Participants were: CMV seropositive
(IgG); without evidence of CMV end-organ disease; CD4+ T cell
count ,100 cells/mm3; and plasma HIV RNA .400 copies/mL
within 30 days prior to entry. Participants must either have been
receiving antiretroviral therapy (ART) continuously for at least
three months, or not be receiving and not planning to initiate
ART. ART was defined as at least a three-drug antiretroviral
regimen, including at least one protease inhibitor (PI) and/or non-
nucleoside reverse transcriptase inhibitor (NNRTI). Participants
on a three-drug nucleoside reverse transcriptase inhibitor (NRTI)
regimen were eligible if treated in the past with a PI or an NNRTI.
ART was prescribed as part of usual clinical care and not
determined by the study protocol. The HIV treatment criteria
were designed to lead to the enrollment of patients who, for
various reasons such as viral resistance and/or medication non-
adherence, were not receiving substantive benefit from ART and
thus were at risk of CMV end-organ disease.
The study design has been described previously and included
enrollment of participants into an observation phase during which
plasma CMV DNA PCR was collected at regular intervals [11].
Those with detectable CMV entered into a randomization phase
and were assigned valganciclovir or placebo. Because there were
no differences between arms in the survival and CMV end organ
disease rates during the randomization phase, morbidity and
mortality data from all participants who were receiving ART for at
least three months and had a suboptimal virologic and immuno-
logic response to ART were included in the present analysis. We
defined suboptimal ART response as an absolute CD4+ T cell
count below 100 cells/mm3 and a plasma HIV RNA level greater
than 1,000 copies/mL at enrollment. This viral load threshold was
selected to exclude those with chronic low-level viremia and
virologic ‘blips’. Of the 338 participants in the trial, 262 (77.5%)
entered the study on ART and, of these, 233 (88.9%) met these
criteria for suboptimal ART response.
Evaluations
Clinical evaluations were conducted every 4–12 weeks. Lym-
phocyte subsets were obtained at baseline and every 16 weeks.
Quantitative plasma HIV RNA PCR (standard HIV-1 RT PCR,
Roche Diagnostics. Indianapolis, IN: lower limit of detection of
400 copies/mL, respectively) was obtained at baseline.
Categorization of Cause of Death
For participants who died during study follow-up, the causes of
death reported by the site investigators (primary cause, four
contributing causes, and a descriptive narrative) were reviewed
independently by the two of the study chairs (DAW and MAJ),
who categorized each death as being due to a condition that was
AIDS-defining (1993 Centers for Diseases Control and Preven-
tion), non-AIDS defining, or of uncertain etiology. In the two cases
where the categorization of a death by the two study chairs did not
agree, an experienced HIV clinician (CvdH) not directly
associated with the study reviewed the data and provided the
final categorization.
Continued ART in Advanced Viremic Patients
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Statistical Methods
The primary endpoints were times to death, AIDS-defining
condition, and serious non-AIDS event. In this study population
participants were often diagnosed with both AIDS-defining
conditions and serious non-AIDS events before dying or
withdrawing from study. Thus, there were events other than the
endpoint of interest that altered the probability of the endpoint.
These events are competing risks.
For the time to death analysis, withdrawing from study was the
competing risk. Time to death was calculated from study entry to
date of death. For participants who withdrew from study before
dying, event times were calculated from study entry to the date of
last clinic visit.
For the time to new AIDS-defining condition analysis, dying
and withdrawing from study were the competing risks. However,
those dying from an AIDS-defining condition were endpoints in
this analysis. Time to new AIDS-defining condition was calculated
from study entry to date of diagnosis of the new AIDS-defining
condition. For participants who died or withdrew from study
before diagnosis of a new AIDS-defining condition, event times
were calculated from study entry to the date of death or last clinic
visit, respectively.
For the time to new serious non-AIDS event analysis, dying
from an AIDS-defining condition or unknown cause of death and
withdrawing from study were the competing risks. However, those
who died from a new serious non-AIDS event were endpoints in
this analysis. Time to new serious non-AIDS event was calculated
from study entry to date of diagnosis of the new serious non-AIDS
event. For participants who died or withdrew from study before
diagnosis of a new serious non-AIDS event, event times were
calculated from study entry to the date of death or last clinic visit,
respectively.
In these time to endpoint analyses, participants who completed
follow-up without an endpoint or competing risk event were
censored, with times calculated from study entry to date of last
clinic visit. Nonparametric cumulative incidence curves were used
to estimate the cumulative incidence function of each endpoint of
interest by accounting for the presence of competing risks. The
cumulative incidence curves were fit using the cuminc function in
S-PLUS (Version 3.4 Release 1 for Sun SPARC, SunOS 5.3 :
1996).
The associations between baseline variables and each time to
endpoint of interest were examined using proportional hazards
regression modeling of sub-distribution functions in competing
risks [12]. Age, race, Karnofsky Performance Score (KPS), and
CD4+ T cell count were a priori dichotomized based on commonly
accepted practice (age, race) or clinical significance (CD4+ T cell
count, KPS). Variables found to be statistically significant (p,0.10)
in the univariable models were examined together in a multivar-
iable model. If both the continuous and dichotomous versions of
the variable were statistically significant in the univariable model,
then the variable that was most significant was included in the
multivariable model. The multivariable model was reduced using
the backward elimination method until all variables were
statistically significant at the 0.05-level. The competing risks
proportional hazards regression models were fit using the
CMPRSK package in R (Copyright 2010, The R Foundation
for Statistical Computing Version 2.12.1 (2010-12-16), ISBN 3-
900051-07-0).
Incidence rates were calculated using standard epidemiological
methods with a 48-week year. Confidence intervals for incidence
rates and crude mortality rates were calculated using the Poisson
distribution and Wilson’s binomial method, respectively, and were
fit using the Stata command cii (Copyright 2009, StataCorp LP
Version 11.1). Comparisons between groups were made using the
Wilcoxon and sign tests for unpaired and paired continuous data,
respectively.
Results
Participant Characteristics
From 2000 to 2004, 233 participants enrolled in the A5030 trial
had been receiving ART prescriptions from a health care provider
for at least three months prior to entry and were neither
virologically suppressed below 1,000 copies/mL nor had substan-
tive immunologic reconstitution at trial entry. The characteristics
of this cohort are detailed in Table 1. The cohort was mostly male
and racially diverse, with a median age of 42 years (range: 20–63).
Their median baseline Karnofsky performance score (KPS) was 90
(range: 60–100), median nadir CD4+ T cell count prior to study
entry (available for 211 participants) was 12/mm3 (range: 0–100),
and median baseline CD4+ T cell count was 30/mm3 (range: 0–
95). Their median baseline plasma HIV RNA was 5 log10 copies/
mL (range: 3.04–6.48). There was minimal change in the
antiretrovirals prescribed by participants’ health care providers
during study follow-up. The mean change in CD4+ T cell count
among the 201 (86.3%) participants with at least one post-baseline
value was 33 cells/mm3 (95% CI= (19, 48)), a small but
statistically significant increase (sign test p = 0.027). On-study
HIV RNA data were not collected.
Mortality
During a median follow-up of 96 weeks (mean: 108; range: 4–
249), 56 (24.0% [95% CI= (19.0%–29.9%)]) of these 233
participants died, for a death incidence rate of 10.7/100 patient-
years (95% CI= (8.1–13.9)). Of these, 42.8% (n= 24) were
reportedly due to an AIDS-defining condition (1993 Centers for
Diseases Control and Prevention) or AIDS progression, 44.6%
Table 1. Baseline Characteristics.
Characteristic
Total
(N=233)
Male [N (%)] 209 (90%)
White, Non-Hispanic [N (%)] 131 (56%)
Black, Non-Hispanic [N (%)] 66 (28%)
Hispanic [N (%)] 32 (14%)
Age [years, median (range)] 42 (20–63)
Karnofsky Performance Score
median (range) 90 (60–100)
,90 [N (%)] 102 (44%)
,80 [N (%)] 33 (14%)
Nadir CD4+ T Cell Count
median (range) [cells/mm3]* 12 (0–100)
,25 [cells/mm3, N (%)]* 197 (70%)
,50 [cells/mm3, N (%)]* 253 (90%)
CD4+ T Cell Count
median (range) [cells/mm3] 30 (0–95)
,25 [cells/mm3, N (%)] 99 (42%)
,50 [cells/mm3, N (%)] 175 (75%)
HIV RNA [log10 copies/mL, median (range)] 5.00 (3.04–6.48)
*Based on 211 participants with available nadir CD4+ T cell counts.
doi:10.1371/journal.pone.0078676.t001
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(n = 25) were reportedly due to a non-AIDS-defining condition
(non-AIDS-defining infectious or malignant diseases, pulmonary
or cardiovascular conditions, or other diseases listed in Table 2),
and 12.5% (n= 7) were of unknown etiology. The median baseline
CD4+ T cell count of those who died was 13/mm3 (range: 0–84).
At the visit prior to death, the median CD4+ T cell count was 7/
mm3 (range: 0–135).
The cumulative incidence curve of time to death is shown in
Figure 1A. Withdrawal from study (n= 61) was the competing risk
for dying. The reasons for study withdrawal included severe
debilitation, unable to get to clinic, withdrawal of consent, and
unable to contact. Participants who withdrew from study were not
significantly different from those who died or were censored with
respect to sex, race, age at entry, KPS, and baseline HIV RNA
Table 2. Reported death causes, AIDS-defining conditions, and serious non-AIDS-defining events.
Death Causes (N=56) N (%*)
AIDS-Defining Conditions
(N=59) N (%*)
Serious Non-AIDS Events
(N=40) N (%*)
Progression of AIDS** 14 (25%) Pneumocystis jirovecii pneumonia 11 (18%) Sepsis 19 (48%)
AIDS-Defining Conditions*** 10 (18%) Cytomegalovirus 10 (17%) Pulmonary Diseases 16 (40%)
Pneumocystis jirovecii pneumonia 3 Candidiasis 9 (15%) Cardiovascular Diseases 1 (3%)
Wasting Syndrome 2 Cryptococcosis 6 (10%) Skin Cancer 1 (3%)
Kaposi’s Sarcoma 2 Wasting Syndrome 4 (6%) Nephropathy 1 (3%)
CNS Lymphoma 2 Kaposi’s Sarcoma 3 (5%) CNS Disease 1 (3%)
Cytomegalovirus 1 Lymphoma 3 (5%) Cirrhosis 1 (3%)
Sepsis 9 (16%) PML**** 3 (5%)
Pulmonary Diseases 5 (9%) Cryptosporidiosis 3 (5%)
Cardiovascular Diseases 4 (7%) CNS Lymphoma 2 (3%)
Other Malignancies (Lung, Laryngeal) 2 (4%) Zoster 1 (2%)
Renal Failure 1 (2%) Toxoplasmosis 1 (2%)
Pulmonary Embolus 1 (2%) Mycobacterium Avian Complex 1 (2%)
Pancytopenia 1 (2%) Isosporiasis 1 (2%)
Lupus 1 (2%) Coccidioidal Meningitis 1 (2%)
Liver Failure 1 (2%)
Unknown Etiology 7 (12%)
*Total % does not add to 100% due to rounding.
**Reported death due to AIDS without AIDS-defining condition.
***Centers for Disease Control and Prevention 1993 AIDS-Defining Conditions.
****Progressive Multifocal Leukoencephalopathy.
doi:10.1371/journal.pone.0078676.t002
Figure 1. Death (56 events), Off Study (61 events) in panel [A]. [B] AIDS-Defining Condition (64 events), Death (27 events), Off
Study (45 events). [C] Serious Non-AIDS Event (52 events), Death (30 events), Off Study (57 events).
doi:10.1371/journal.pone.0078676.g001
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(p.0.10; data not shown). However, those who withdrew from
study had significantly higher baseline CD4+ T cell counts than
those who died, with a median of 32/mm3 (range: 2–83; Wilcoxon
test p,0.001). At the visit prior to withdrawal, the median CD4+
T cell count was 23/mm3 (range: 0–386).
In univariable competing risks proportional hazards regression
analyses, a decreased hazard of dying was significantly associated
Table 3. Univariable competing risks analyses of times to death, new AIDS-defining conditions, and new serious non-AIDS-
defining events.
Death AIDS-Defining Conditions Serious Non-AIDS Events
Variable
Estimated
HR 95% CI P-Value
Estimated
HR 95% CI P-Value
Estimated
HR 95% CI P-Value
Baseline Age
per 10-years older 1.11 (0.72, 1.69) 0.64 1.17 (0.81, 1.68) 0.41 0.94 (0.57, 1.55) 0.81
$40 vs ,40 0.91 (0.53, 1.57) 0.74 1.29 (0.76, 2.18) 0.34 1.06 (0.60, 1.88) 0.85
Sex
male vs female 2.00 (0.63, 6.32) 0.24 1.73 (0.63, 4.76) 0.29 1.30 (0.45, 3.78) 0.62
Race
white vs non-white 1.02 (0.603, 1.72) 0.95 1.49 (0.89, 2.50) 0.13 0.98 (0.56, 1.69) 0.93
black vs non-black 0.84 (0.46, 1.56) 0.59 0.27 (0.12, 0.61) 0.002 0.95 (0.51, 1.75) 0.87
Baseline Karnofsky Performance Score
$80 vs ,80 0.60 (0.30, 1.23) 0.16 0.48 (0.25, 0.91) 0.023 0.83 (0.39, 1.77) 0.64
$90 vs ,90 0.57 (0.34, 0.96) 0.036 0.62 (0.38, 1.004) 0.052 0.81 (0.47, 1.39) 0.44
Nadir CD4+ T Cell Count
per 10-cells/mm3 higher 0.74 (0.61, 0.89) 0.002 1.06 (0.95, 1.18) 0.32 0.85 (0.71, 1.03) 0.094
$25 vs ,25 cells/mm3 0.38 (0.18, 0.81) 0.012 1.33 (0.78, 2.25) 0.29 0.70 (0.37, 1.32) 0.27
$50 vs ,50 cells/mm3 (-) (-) DNC* 0.98 (0.45, 2.15) 0.96 0.53 (0.17, 1.64) 0.27
Baseline CD4+ T Cell Count
per 10-cells/mm3 higher 0.75 (0.64, 0.87) 0.0002 0.94 (0.85, 1.04) 0.22 0.86 (0.75, 0.99) 0.030
$25 vs ,25 cells/mm3 0.29 (0.16, 0.52) ,0.0001 0.69 (0.42, 1.12) 0.13 0.47 (0.27, 0.82) 0.007
$50 vs ,50 cells/mm3 0.25 (0.10, 0.63) 0.003 0.74 (0.42, 1.28) 0.28 0.67 (0.34, 1.31) 0.24
Baseline HIV RNA
per 1-log10 copies/mL lower 0.76 (0.49, 1.18) 0.22 0.60 (0.42, 0.87) 0.007 0.79 (0.52, 1.19) 0.26
*DNC=model did not converge.
doi:10.1371/journal.pone.0078676.t003
Table 4. Multivariable competing risks analyses of times to death, new AIDS-defining conditions, and new serious non-AIDS-
defining events.
Death AIDS-Defining Conditions Serious Non-AIDS Events
Variable
Estimated
HR 95% CI P-Value
Estimated
HR 95% CI P-Value
Estimated
HR 95% CI P-Value
Race
black vs non-black (-) (-) (-) 0.30 (0.13, 0.69) 0.005 (-) (-) (-)
Baseline Karnofsky Performance Score
$80 vs ,80 (-) (-) (-) 0.50 (0.27, 0.94) 0.030 (-) (-) (-)
$90 vs ,90 0.56 (0.32, 0.97) 0.038 (-) (-) (-) (-) (-) (-)
Nadir CD4+ T Cell Count; per 10-cells/mm3
higher
0.75 (0.62, 0.91) 0.003 (-) (-) (-) 0.97 (0.79, 1.20) 0.80
Baseline CD4+ T Cell Count
$25 vs ,25 cells/mm3 (-) (-) (-) (-) (-) (-) 0.46 (0.22, 0.94) 0.034
Baseline HIV RNA
per 1-log10 copies/mL lower (-) (-) (-) 0.66 (0.45, 0.96) 0.031 (-) (-) (-)
doi:10.1371/journal.pone.0078676.t004
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with baseline KPS $90 (HR=0.57; 95% CI= (0.34,0.96);
p = 0.036), higher nadir CD4+ T cell count (HR=0.74 per 10-
cells/mm3; 95% CI= (0.61,0.89); p = 0.002), nadir CD4 $25/
mm3 (HR=0.38; 95% CI= (0.18,0.81); p = 0.012), baseline CD4+
T cell count (HR=0.75 per 10-cells/mm3; 95% CI= (0.64,0.87);
p = 0.0002), baseline CD4 $25/mm3 (HR=0.29; 95%
CI= (0.16,0.52); p,0.0001), and baseline CD4 $50/mm3
(HR=0.25; 95% CI= (0.10,0.63); p = 0.003; Table 3). In the
final multivariable analysis, baseline KPS $90 (HR=0.56; 95%
CI= (0.32,0.97); p = 0.038) and nadir CD4+ T cell count
(HR=0.75 per 10-cells/mm3; 95% CI= (0.62,0.91); p = 0.003;
Table 4) were significantly associated with a decreased adjusted
hazard of dying.
AIDS-Defining Conditions
At least one new AIDS-defining condition developed in 25.3%
(n= 59) participants receiving ART prescriptions at entry, with a
median follow-up of 78 weeks (mean: 93; range: 3–249). Five
additional participants died with an AIDS-defining condition, for a
new AIDS-defining condition incidence rate of 14.2/100 person-
years (95% CI= (10.9,18.1)). Pneumocystis jirovecii pneumonia,
CMV (retinitis or colitis), esophageal candidasis, cryptococcal
infection, wasting syndrome, KS, lymphomas, PML, and crypto-
sporidia infection together accounted for over 90% of these events
(Table 2). The median CD4+ T cell count of those who developed
a new AIDS-defining condition was 25/mm3 (range: 1–90) at
entry and 13/mm3 (range: 0–127) at the visit before the new
AIDS-defining condition diagnosis.
The cumulative incidence curve of time to new AIDS-defining
condition is shown in Figure 1B. Death (n= 27) and withdrawal
from study (n= 45) were competing risks for developing a new
AIDS-defining condition. In univariable proportional hazards
competing risks regression analyses, a decreased hazard of
developing a new AIDS-defining condition was significantly
associated with black race (HR=0.27; 95% CI= (0.12,0.61);
p = 0.002) baseline KPS $80 (HR=0.48; 95% CI= (0.25,0.91);
p = 0.023), baseline KPS $90 (HR=0.62; 95% CI= (0.38,1.004);
p = 0.052), and lower baseline log10 HIV RNA (HR=0.60 per 1
log10 copies/mL; 95% CI= (0.42,0.87); p = 0.007; Table 3). In
multivariable analysis, black race (HR=0.30; 95%
CI= (0.13,0.69); p = 0.005), baseline KPS $80 (HR=0.50; 95%
CI= (0.27,0.94); p = 0.030), and lower baseline HIV RNA
(HR=0.66 per 1-log10 copies/mL; 95% CI= (0.45,0.96);
p = 0.031; Table 4) were significantly associated with a decreased
adjusted hazard of developing a new AIDS-defining condition.
Serious Non-AIDS-Defining Events
New serious non-AIDS-defining events were reported for 17.2%
(n= 40) of the participants receiving ART prescriptions at entry; in
an additional 12, the event was fatal. With a median follow-up of
81 weeks (mean: 98; range: 1–249), the new serious non-AIDS-
defining event incidence rate was 11.0/100 person-years (95%
CI= (8.2,14.4)). Sepsis and pulmonary diseases accounted for
nearly 90% of these events (Table 2). The median CD4+ T cell
count for those who reported a new serious non-AIDS-defining
event was 15/mm3 (range: 0–89) at entry and 9/mm3 (range: 0–
135) at the visit prior to the new serious non-AIDS-defining event.
The cumulative incidence curve of time to new serious non-
AIDS-defining event is shown in Figure 1C. Death (n = 30) and
withdrawal from study (n= 57) were competing risks for reporting
a new serious non-AIDS-defining event. In univariable competing
risks proportional hazards regression analyses, a decreased hazard
of reporting a new serious non-AIDS event was significantly
associated with higher nadir CD4+ T cell count (HR=0.85 per
10-cells/mm3; 95% CI= (0.71,1.03); p = 0.094), higher baseline
CD4+ T cell count (HR=0.86 per 10-cells/mm3; 95%
CI= (0.75,0.99); p = 0.030), and baseline CD4+ T cell count
$25/mm3 (HR=0.47; 95% CI= (0.27,0.82); p = 0.007); Table 3).
With nadir CD4+ T cell count and baseline CD4+ T cell count in
the multivariable model, only baseline CD4+ T cell count $25/
mm3 remained significant (HR=0.46; 95% CI= (0.22,0.94);
p = 0.034; Table 4).
Discussion
In a cohort of individuals with very advanced HIV disease who
had been prescribed ART and failed to achieve complete virologic
suppression and substantive immune reconstitution prior to
enrollment between 2000 and 2004, mortality was lower than
reported in comparable cohorts studied in the early 1990s (a time
when modern antimicrobial prophylaxis for opportunistic infec-
tions and nucleoside-reverse-transcriptase-inhibitor [NRTI]-only
antiretroviral regimens were widely available). The 233 partici-
pants in this cohort enrolled in the A5030 protocol between 2000
and 2004 with a median CD4+ T cell count of 30/mm3, plasma
HIV RNA of 5 log10 copies/mL, and Karnofsky Performance
Score of 90 had 24.0% (95% CI= (19.0%,29.9%) mortality during
a median of 24.1 (mean: 26.9) months of follow-up. In contrast,
333 participants with a median CD4+ T cell count of 30/mm3 and
mean Karnofsky Performance Score of 86 who were assigned to
active drug in a randomized trial of clarithromycin for M. avium
complex prophylaxis a decade earlier, had a 32% (95%
CI= (27.3%,37.3%)) mortality during a mean 15 months of
follow-up [7]. During this same time period, 699 participants with
a median CD4+ T cell count of 23/mm3 who were assigned a
variety of zidovudine and/or didanosine and/or zalcitabine
antiretroviral regimens had 40% (95% CI= (36.5%,43.7%))
mortality after a median of 18 months of follow-up [8], and 566
participants with a CD4+ T cell count of 50–75/mm3 assigned to
active drug in a randomized trial of rifabutin for M. avium complex
prophylaxis had 35% (95% CI= (31.3%,39.2%)) mortality during
a mean follow-up of approximately two years. This suggests that
even in the most advanced AIDS patients who obtain little, if any,
objective immunologic or virologic benefit from modern antiretro-
viral treatment, ART may improve survival compared to NRTI-
only therapy.
One way by which ART might alter the natural history of AIDS
in such ‘‘treatment failure’’ patients is to reduce the proportion of
deaths caused by AIDS-defining conditions. In the HIV Outpa-
tient Study, the proportions of deaths due to AIDS-defining
conditions was 87% in 1996, prior to widespread use of modern
ART regimens, but decreased to 57% by 2004 [13]. The rise of
non-AIDS-defining conditions as a cause of death followed an
incremental increase in CD4+ T cell counts at the time of death in
this study (from 59/mm3 in 1996 to 287/mm3 in 2004), and non-
AIDS deaths were associated with higher CD4+ T cell counts at
the time of ART initiation. In our investigation, non-AIDS-
defining causes of death equaled AIDS-defining causes of death
despite much lower CD4+ T cell counts among those who died.
The finding of high rates of non-AIDS-defining causes of death
in our cohort of patients with profoundly low CD4+ T cell counts
mirrors data from a mortality analysis of the pooled antiretroviral-
receiving control arms of the ESPRIT and SILCAAT trials, where
rates of AIDS- and non-AIDS deaths were similar and low CD4+
T cell counts were associated with not only all-cause mortality, but
also fatal non-AIDS events [14]. In that analysis, most of these
deaths occurred among those with CD4+ T cell counts below 50/
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mm3, however, a substantial proportion was also observed at
higher counts.
The shift over time in mortality from the AIDS events of the
pre-modern-ART era to conditions that have not traditionally
been considered a consequence of HIV disease progression
suggests a potential protective effect of modern ART regimens
in preventing death from AIDS-defining conditions, even among
patients with persistent low CD4+ T cell counts and uncontrolled
HIV replication. In the A5030 trial, when analyzing both the 272
antiretroviral-treated and the 65 -untreated participants, receipt of
ART at study entry was significantly associated with a decreased
hazard of developing a new AIDS-defining condition (HR=0.44;
95% CI= (0.28,0.68); p = 0.0002, data not shown). That ART,
even when not achieving suppression of HIV replication or
substantive reconstitution of immune function, may provide some
protection against opportunistic infections is further supported by
our earlier finding of lower rates of CMV disease than expected
based on pre-modern-ART era data in this cohort of patients with
advanced AIDS [11].
Consistent with much larger cohort studies, 7% of the deaths
among those included in this analysis were attributed to
cardiovascular disease. Like several of the other non-AIDS-
defining causes of death in our study, cardiovascular disease may
be associated with chronic inflammation [15]. Markers of
inflammation and coagulation were not collected; however, recent
data point to a strong correlation between uncontrolled HIV
replication and these markers [15–20]. It is possible that in the
setting of prophylaxis against opportunistic infections and a partial
protective ART effect, survival was long enough for conditions
triggered or exacerbated by chronic inflammation to emerge.
Other than factors related to HIV therapy and CD4+ T cell
count, there were few other covariates associated with serious
and/or fatal outcomes. Blacks were less likely to develop a new
AIDS-defining condition compared to non-blacks, but there were
no racial differences in the risk of death or for serious non-AIDS-
defining events.
There are limitations that should be considered when
interpreting these findings. Foremost, the causes of death were
those reported from ACTG study sites and were not determined
through independent reviews of death certificates or primary,
medical-record source documents. Based on the data that were
available from the sites, categorization of the causes of death was
made by the study chairs (both HIV clinicians) with an
independent expert HIV clinician adjudicating two cases of
discordant categorization. In addition, the cohort consisted of
patients who were enrolled in a clinical trial, and the supervision
afforded by the study may have led to greater than usual attention
to prophylaxis of opportunistic infections and clinical monitoring.
Lastly, many participants prematurely withdrew from follow-up,
some due to debility that may have represented an AIDS-related
or non-AIDS-related event. Therefore, the study outcomes
competed with one another and with study withdrawal. However,
the analysis methods accounted for these competing risks to
appropriately summarize the survival curves and to appropriately
assess associations between baseline covariates and the events of
interest in the regression analyses. In addition, our comparisons to
historical controls permit many biases. It is possible that
virologically non-suppressive, immunologically ineffective ART is
of no clinical benefit and that the difference in survival observed
between the A5030 cohort and historical trials from a decade
earlier represents other improvements in medical care for patients
with advanced AIDS. Nevertheless, baseline CD4+ T counts of the
three historical cohorts were comparable and follow-up was often
shorter than in A5030 cohort. Further, the prophylaxis for
opportunistic infections in advanced AIDS has changed little from
the early 1990s to early 2000s (only the active M. avium complex
prophylaxis arms from historical trials were included in our
comparisons).
In conclusion, patients receiving modern ART regimens but
who, as a consequence of antiretroviral drug resistance and/or
suboptimal medication adherence, had persistent very low CD4+
T cell counts and failed to achieve complete virologic suppression
were found to be at high risk of death, particularly from non-AIDS
causes, though lower than that reported in patients with
comparable CD4+ T cell counts receiving optimal opportunistic
infection prophylaxis and antiretroviral therapy in the pre-
modern-ART era. The lower than expected rates of opportunistic
conditions observed in this cohort also suggest a potential
protective effect of apparently ineffective ART against the
development of such conditions. Overall, these findings support
continued prescription of ART to patients with advanced AIDS
who appear to obtain little, if any, virologic or immunologic
benefit from their HIV therapy.
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